股价一度跌近2%！阿斯利康(AZN.US)狼疮药自行注射剂型申请遭FDA驳回

智通财经02-03

智通财经APP获悉，美国食品药品监督管理局(FDA)近日驳回了阿斯利康(AZN.US)狼疮治疗药物的自行注射剂型上市申请，不过这家英国制药企业表示，目前仍在与监管机构沟通，推进该申请的审批进程。阿斯利康于周二发布声明称，公司已按FDA完整回复函的要求提交相关资料，并将致力于“尽快推进申请进程”。受此消息影响，阿斯利康在伦敦股市早盘一度下跌1.9%，几乎回吐全年涨幅。这款名为Saphnelo的药物...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608294608?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-03 17:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608294608","market":"fut","top_or_hot":-1,"title":"股价一度跌近2%！阿斯利康(AZN.US)狼疮药自行注射剂型申请遭FDA驳回","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，美国食品药品监督管理局(FDA)近日驳回了阿斯利康(AZN.US)狼疮治疗药物的自行注射剂型上市申请，不过这家英国制药企业表示，目前仍在与监管机构沟通，推进该申请的审批进程。阿斯利康于周二发布声明称，公司已按FDA完整回复函的要求提交相关资料，并将致力于“尽快推进申请进程”。受此消息影响，阿斯利康在伦敦股市早盘一度下跌1.9%，几乎回吐全年涨幅。这款名为Saphnelo的药物...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401056.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>股价一度跌近2%！阿斯利康(AZN.US)狼疮药自行注射剂型申请遭FDA驳回</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n股价一度跌近2%！阿斯利康(AZN.US)狼疮药自行注射剂型申请遭FDA驳回\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-03 17:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1401056.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，美国食品药品监督管理局(FDA)近日驳回了阿斯利康(AZN.US)狼疮治疗药物的自行注射剂型上市申请，不过这家英国制药企业表示，目前仍在与监管机构沟通，推进该申请的审批进程。阿斯利康于周二发布声明称，公司已按FDA完整回复函的要求提交相关资料，并将致力于“尽快推进申请进程”。受此消息影响，阿斯利康在伦敦股市早盘一度下跌1.9%，几乎回吐全年涨幅。这款名为Saphnelo的药物...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401056.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1401056.html","article_id":"2608294608","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608294608","pubTimestamp":1770110175,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，美国食品药品监督管理局近日驳回了阿斯利康狼疮治疗药物的自行注射剂型上市申请，不过这家英国制药企业表示，目前仍在与监管机构沟通，推进该申请的审批进程。此次阿斯利康提交的为皮下注射剂型申请，若获批，患者可实现每周自行注射给药。阿斯利康方面披露，全球范围内受该疾病困扰的患者超340万人。据悉，FDA预计将在今年上半年对阿斯利康提交的补充申请作出审批决定，在此期间，该药物的静脉注射剂型仍正常供应。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AZN":"阿斯利康","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4007":"制药","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC"},"translate_title":"The stock price once fell nearly 2%! AstraZeneca's (AZN.US) lupus drug self-injection dosage form application rejected by FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1.5},"content_text":"智通财经APP获悉，美国食品药品监督管理局(FDA)近日驳回了阿斯利康(AZN.US)狼疮治疗药物的自行注射剂型上市申请，不过这家英国制药企业表示，目前仍在与监管机构沟通，推进该申请的审批进程。阿斯利康于周二发布声明称，公司已按FDA完整回复函的要求提交相关资料，并将致力于“尽快推进申请进程”。受此消息影响，阿斯利康在伦敦股市早盘一度下跌1.9%，几乎回吐全年涨幅。这款名为Saphnelo的药物目前已有静脉注射剂型获批上市，患者需每四周前往医院或诊所接受静脉注射治疗。此次阿斯利康提交的为皮下注射剂型申请，若获批，患者可实现每周自行注射给药。汇编数据显示，分析师预测该药物到2031年年度营收有望突破16亿美元。Saphnelo用于治疗系统性红斑狼疮，该疾病是一种自身免疫性疾病，患者的免疫系统会错误攻击自身健康组织。阿斯利康方面披露，全球范围内受该疾病困扰的患者超340万人。欧盟已于去年12月批准Saphnelo的皮下注射剂型。一项关于Saphnelo自行注射剂型的后期临床试验显示，与安慰剂相比，该药物能有效降低疾病严重程度。据悉，FDA预计将在今年上半年对阿斯利康提交的补充申请作出审批决定，在此期间，该药物的静脉注射剂型仍正常供应。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608294608","isCrawlerRequest":true}